login

Chronic Myelogenous Leukemia — New Concepts

New England Journal of MedicinePublished 14 May 1981
H. Phillip Koeffler, David W. Golde
Citations245
SJR quartileQ1
SJR score19.08
SNIP13.47

TL;DR

A large number of patients diagnosed with chronic myelogenous leukemia with a marked prophylactic response to chemotherapy also have a history of atypical Irving's disease.

Abstract

CHRONIC myelogenous leukemia (CML) is a clonal myeloproliferative disorder arising from neoplastic transformation at the level of the pluripotent stem cell and characterized clinically by a marked overproduction of granulocytes. The disease was probably first identified in 1845 by Craigie,1 Bennett,2 and Virchow,3 who called attention to the prominent splenomegaly and "suppuration of the blood." In 1960, Nowell and Hungerford described an abnormal, small chromosome (the Philadelphia, or Ph1, chromosome) in patients with this disorder.4 Because of the typical clinical picture and the specific chromosomal abnormality, CML is perhaps the best defined of the myeloproliferative disorders. In western countries, . . .

Keywords

Medicine